Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Jubilant DraxImage is proud to be a leader in the development of therapeutics intended to treat rare and serious conditions. These efforts are aligned with the Value that Nuclear Medicine can bring to improve precise, patient focused treatment.
131I-MIBG localizes to adrenergic tissue [neuroectodermal] via a norepinephrine re-uptake mechanism.
Some of the cancers rich in adrenergic tissue include Neuroblastoma, Pheochromocytoma and Paraganglioma. For example, Neuroblastoma is a difficult to treat childhood cancer and those children with resistant or relapsed disease, after current treatment options are exhausted, have very poor survival.
Our investigational agent, 131I-MIBG, is currently being studied in Neuroblastoma under clinical research protocols. Please consult those organizations at
NANT https://clinicaltrials.gov/ct2/show/NCT02035137?term=nant&rank=4 and COG https://www.childrensoncologygroup.org/index.php/research-collaborations.
For additional information please consult ClinicalTrials.gov.
NOTE: MIBG labeled with I-131 is currently not approved by FDA in the US nor approved for sale by Health Canada in Canada.